1-3 of 3
Ilana Slouzkey
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The ELN 2022 Risk Stratification Has No Impact on the Dismal Prognosis of Patients with Acute Undifferentiated Leukemia

Baher Krayem, Tsila Zuckerman, Avraham Frisch, Ilana Slouzkey, Tehila Azoulay, Michal Karmona, Liran I. Shlush, Nathali Kaushansky, Noa Chapal-Ilani, Shimrit Ringelstein-Harlev
Journal: Blood
Blood (2023) 142 (Supplement 1): 4221.
https://doi.org/10.1182/blood-2023-188592
Published: 2023
Journal Articles

Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse

Yishai Ofran, MD, Chezi Ganzel, MD, Shimrit Harlev, MD PhD, Ilana Slouzkey, PhD, Ofrat Beyar Katz, MD, Michal Hayun, PhD, Mira Kharit, MD, Jacob M. Rowe, MD, Avraham Frisch, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5206.
https://doi.org/10.1182/blood-2018-99-111258
Published: 2018
Journal Articles

Clinical Features, Laboratory Characteristics, and Response to Therapy in Patients with Acute Undifferentiated Leukemia

Shimrit Harlev, MD PhD, Tehila Azoulay, Margrita Filatov, Galit Sarig, PhD, Ilana Slouzkey, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1505.
https://doi.org/10.1182/blood-2018-99-118033
Published: 2018